NeuroScientific Biopharmaceuticals Ltd (ASX: NSB) has engaged leading neuroimaging company Imeka of Canada to utilise its powerful biomarker technology to determine the effect of EmtinB in preclinical and clinical development programmes.
Imeka’s cutting-edge imaging technology involves the use of magnetic resonance imaging (MRI) and powerful software to visualize and quantify different aspects of the brain’s white matter, a method called diffusion MRI (dMRI).
Additionally, Imeka is the world’s leading company in combining artificial intelligence (AI) and deep learning with dMRI to map structures and neural networks of the brain. The non-invasive technology measures aspects such as apparent fibre density (AFD), extracellular water fraction (white matter free water), and tissue radial diffusivity (tRD), to gain valuable insights into axonal loss, neuroinflammation, and demyelination. Traditional MRI and PET-CT imaging techniques do not allow analysis of microstructures within the brain to the sensitivity and specificity of dMRI.
CEO and Managing Director, Matt Liddelow, said NeuroScientific will initially incorporate Imeka’s dMRI technology into the company’s Multiple sclerosis (MS) R&D programme, with plans to widen its use across future clinical studies. NeuroScientific recently announced it has partnered with specialist contract research organisation BioSpective to accelerate its MS R&D programme
NeuroScientific Biopharmaceuticals is committed to finding solutions for neurodegenerative conditions and strongly believes our lead drug candidate, EmtinB, is one of the most promising drugs currently in development for the treatment of Alzheimer’s disease and Multiple sclerosis,” Mr Liddelow said.
“The company is also committed to collaborating with world-leading companies such as Imeka that are advancing game-changing imaging technologies that we can use to further demonstrate the treatment effect of EmtinB in the human brain with a degree of certainty that is otherwise not possible.
“Combined with traditional outcome measures, we believe Imeka’s diffusion MRI technology will allow us to characterise the disease-modifying effects of EmtinB in patients and firmly position EmtinB as a first-in-class treatment for neurodegenerative conditions, especially in Multiple sclerosis.”
